Penis enlargement

1. A method for causing a permanent increase in the length and girth of a male subject's penis, said method comprising the step of (a) administering to said male an effective amount of a vasodilator selected from the group consisting of papaverine, chlorpromazine, atropine, phentolamine, and prostaglandin E1, or a mixture thereof, and relaxin, which potentiates the effect of the vasodilator and compositions thereof comprising a pharmaceutically-acceptable diluent or carrier, to induce a cumulative prolonged engorgement of the subject's penis; and (b) repeating step (a) as necessary to cause said increase during said treatment.

2. A method as defined in claim 1 , wherein said vasodilator is in admixture with a pharmaceutically-acceptable diluent or carrier,

3. A method as defined in claim 1 , wherein said administration is such that said prolonged engorgement is sustained for at least 3.5 hours.

4. A method as defined in claim 3 , wherein said prolonged engorgement is sustained for at least 4 hours.

5. A method as defined in claim 1 , wherein said vasodilator is administered as one dose in said treatment step throughout the prolonged engorgement.

6. A method as defined in claim 1 , wherein said vasodilator is administered as at least two doses as defined in said treatment throughout the prolonged engorgement.

7. A method as defined in claim 6 , wherein the engorgement comprises a first erectile response of at least 65%, and a second dose or subsequent doses are administered after the first erectile response falls below 65% during said treatment.

8. A method as defined in claim 5 or claim 6 , wherein said treatment is applied to said patient at least two times per week for a period of at least one month.

9. A method as defined in claim 8 , wherein said treatment is applied to said patient at least four times per week for a period of at least 3 months.

10. A method as defined in claim 1 , wherein the length of the fully erect penis has increased by at least 5% after a treatment period of 12 to 18 months.

11. A method as defined in claim 10 , wherein the length of the fully erect penis is increased by at least 30% after a treatment period of 12 to 18 months.

12. A method as defined in claim 1 , wherein the girth of the fully erect penis is increased by at least 5% after a treatment period of 12 to 18 months.

13. A method as defined in claim 12 , wherein the girth of the fully erect penis is increased by at least 30% after a treatment period of 12 to 18 months.

14. A method as defined in claim 1 , wherein said engorgement comprises a 75-100% erectile response for at least 90% of the time of the prolonged engorgement.

15. A method as defined in claim 1 , wherein said engorgement comprises a 75-100% erectile response for 50-90% of the time of the prolonged engorgement.

16. A method as defined in claim 1 , wherein said engorgement comprises a 75-100% erectile response for up to 50% of the time of the prolonged engorgement.

17. A method as defined in claim 1 , wherein said engorgement comprises a 40-75% erectile response for at least 3 hours.

18. A method as defined in claim 1 , wherein said vasodilator is prostaglandin E1.

19. A method as defined in claim 1 , wherein said vasodilator is formulated for administration by direct injection to the cavernosal tissue, by needle, auto-injector, slow sustained injection pump, high pressure injection device, microinfusion pump, urethral suppository, or implantable sustained release drug or device.

20. A method as defined in claim 1 , wherein said vasodilator is formulated for systemic administration by oral, sublingual, or suppository administration, intravenous administration by needle, auto-injector, slow sustained injection pump, high pressure injection device, microinfusion pump, or implantable sustained release drug or device, or topical administration, such as through the use of creams, lotions or patches.

21. A method as defined in claim 1 , wherein said vasodilator is administered to the dense connective tissue surrounding the erectile tissue of the penis by a deep injection that goes below the dermis and subcutaneous tissues.

22. A method as defined in claim 1 , wherein said vasodilator is administered as an intracavernosal injection.

23. A method as defined in claim 19 , wherein said vasodilator is administered as an implantable sustained release drug or device.

24. A method as defined in claim 18 , wherein said prostaglandin E1 is administered at a dosage of 0.5 to 100 micrograms/kg body weight/day by intracavernosal injection.

25. A method as defined in claim 18 , wherein the prostaglandin E1 is administered systemically at a dosage of 2 to 10,000 microgramslkg body weight/day by an implantable sustained release drug or device.

26. A method as defined in claim 1 , wherein the relaxin is administered by direct injection to the cavernosal tissue, by needle, auto-injector, slow sustained injection pump, high pressure injection device, microinfusion pump, urethral suppository, or implantable sustained release drug or device.

27. A method as defined in claim 1 , wherein the relaxin is systemically administered by oral, sublingual, or suppository administration, intravenous administration by needle, auto-injector, slow sustained injection pump, high pressure injection device, microinfusion pump, or implantable sustained release drug or device, or topical administration, such as through the use of creams, lotions or patches.

28. A method as defined in claim 1 , wherein the relaxin is administered to the dense connective tissue surrounding the erectile tissue of the penis by a deep injection that is well below the dermis and subcutaneous tissues.

29. A method as defined in claim 1 , wherein the relaxin is administered by intracavernosal injection.

30. A method as defined in claim 1 , wherein the relaxin is administered as an implantable sustained release drug or device.

31. A method as defined in claim 1 , wherein the relaxin is administered separately from the composition.

32. A method as defined in claim 1 , wherein the relaxin is administered concurrently with the composition.

33. A method as defined in claim 1 , wherein the relaxin is administered more than once during said treatment.

34. A method as defined in claim 1 , wherein relaxin is administered at a dosage of 0.02 to 1 micrograms/kg body weight/day by intracaversonal injection.

35. A method as defined in claim 1 wherein relaxin is topically administered at a dosage of 25 to 400 micrograms/kg body weight/day.

36. A method as defined in claim 1 , wherein relaxin is administered at a dosage of 0.02 to 1 micrograms/kg body weight/day by injection into the dense connective tissue of the erectile tissue surrounding the penis.

37. A method as defined in claim 1 , comprising applying a device to prolong the retention of the composition in the penis.

38. A method as defined in claim 37 , comprising fitting said device in the form of a ring around the base of the penis.